NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover

Rhea-AI Filing Summary

NovoCure Ltd Chief Operating Officer Paravasthu Mukund reported mandated tax-related share sales. He sold a total of 1,963 ordinary shares in open-market transactions, including 1,555 shares on February 27, 2026 at a weighted average price of $13.6638 and 408 shares on March 2, 2026 at a weighted average price of $13.4930.

The filing notes these shares were sold to cover tax withholding obligations arising from vesting of Restricted Stock Units under NovoCure’s equity incentive plans, and the sales were required by a “sell to cover” arrangement rather than being discretionary trades. After these transactions, Mukund directly owns 76,343 ordinary shares.

Insider Trade Summary

Net Seller: 1,963 shares ($26,752)

Net Sell 2 txns

Insider Paravasthu Mukund

Role Chief Operating Officer

Sold 1,963 shs ($27K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	408	$13.493	$6K
Sale	Ordinary Shares	1,555	$13.6638	$21K

Holdings After Transaction: Ordinary Shares — 76,343 shares (Direct)

Footnotes (1)

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paravasthu Mukund

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/27/2026		S		1,555(1)	D	$13.6638(2)	76,751	D
Ordinary Shares	03/02/2026		S		408(1)	D	$13.493(3)	76,343	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price.

3. This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Paravasthu, Mukund	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NovoCure (NVCR) COO Paravasthu Mukund report in this Form 4?

He reported selling 1,963 NovoCure ordinary shares in two open-market transactions. The filing explains these sales were required to cover tax withholding obligations from vesting Restricted Stock Units, under a mandated “sell to cover” provision in the company’s equity incentive plans.

How many NovoCure (NVCR) shares did the COO sell and at what prices?

Paravasthu Mukund sold 1,555 ordinary shares at a weighted average price of $13.6638 and 408 shares at $13.4930. Both transactions were executed in multiple trades within disclosed price ranges, and the reported prices represent weighted averages of those trades.

Why were NovoCure (NVCR) shares sold by the COO according to the Form 4?

The filing states the shares were sold solely to satisfy tax withholding obligations triggered by the vesting of Restricted Stock Units. NovoCure’s award agreement requires these obligations to be funded through a “sell to cover” transaction, so the sales were not discretionary trades by the COO.

How many NovoCure (NVCR) shares does the COO own after these transactions?

After the reported “sell to cover” transactions, Paravasthu Mukund directly owns 76,343 NovoCure ordinary shares. This balance reflects his holdings following the sale of 1,963 shares used to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Were the NovoCure (NVCR) COO’s share sales open-market transactions?

Yes. The Form 4 classifies both transactions as open-market sales, code “S.” However, the filing clarifies they were mandated “sell to cover” trades executed to fund tax withholding on RSU vesting, rather than discretionary investment decisions by the COO.